Role of MGMT as biomarker in colorectal cancer

doi:10.12998/wjcc.v2.i12.835

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6710)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

405

WORD

293

HTML

3760

Tables (1-1)

184

Sum=4642

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1144

Download

924

Sum=2068

Dec 16, 2014 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Dec 16, 2014; 2(12): 835-839
Published online Dec 16, 2014. doi: 10.12998/wjcc.v2.i12.835

Role of MGMT as biomarker in colorectal cancer

Alessandro Inno, Giuseppe Fanetti, Maria Di Bartolomeo, Stefania Gori, Claudia Maggi, Massimo Cirillo, Roberto Iacovelli, Federico Nichetti, Antonia Martinetti, Filippo de Braud, Ilaria Bossi, Filippo Pietrantonio

Alessandro Inno, Stefania Gori, Massimo Cirillo, Medical Oncology Department, Ospedale Sacro Cuore Don Calabria, Negrar, 37100 Verona, Italy

Giuseppe Fanetti, Radiotherapy Unit, European Institute of Oncology, 20100 Milan, Italy

Maria Di Bartolomeo, Claudia Maggi, Roberto Iacovelli, Federico Nichetti, Antonia Martinetti, Filippo de Braud, Ilaria Bossi, Filippo Pietrantonio, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy

Author contributions: All authors gave substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; drafting the article or revising it critically for important intellectual content; final approval of the version to be published.

Correspondence to: Filippo Pietrantonio, MD, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 20100 Milan, Italy. filippo.pietrantonio@istitutotumori.mi.it

Telephone: +39-2-23903807 Fax: +39-2-23902149

Received: July 23, 2014
Revised: September 1, 2014
Accepted: October 14, 2014
Published online: December 16, 2014

Core Tip

Core tip: O⁶-methylguanine DNA methyltransferase (MGMT) methylation is involved in colorectal carcinogenesis and represents a predictive biomarker for alkylating agents in metastatic colorectal cancer. In fact, patients with chemorefractory metastatic colorectal cancer with MGMT methylation derived promising response from treatment with dacarbazine or temozolomide, and ongoing research is investigating the efficacy of temozolomide in combination with other chemotherapy drugs for MGMT-methylated colorectal cancer. Future challenges include the combination with biologic drugs and the research for additional biomarkers.